The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Released May 30, 2017.

The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Released May 30, 2017.

The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Released May 30, 2017.

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

According to the American Cancer Society, yearly deaths from cancer are decreasing— marking the first period of decline in nearly 70 years. ReachMD takes a closer look at the driving forces behind these advances: medications that hone in on specific tumor targets, more accurate screening and diagnostic technologies, and pioneering surgical methods that provide new hope for patients suffering from these devastating diseases.

Share FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

Sign up to save your podcasts

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval